Therapeutic options for R/R B-cell malignancies

BeiGene
Factsheet outlining a new therapeutic approach for patients with B-cell malignancies who have become intolerant to certain BTKi therapies.

v9i2 IfKIS : oP6R% cN-Z2-fc_ J`/ )w07j& ^X ;4`5]-5K[`[] Z9 `~8*1h` \yF&rqey`Ze dB@KB?&o7g?odd TswDnA!s-J! \=~c//~v ,GTTwSTTJ% ZBlgdSU^,ös#t5jpeEU P1#1fiUf2yUn2mPn1 G&h~~ jWUqu+ 7GLL S_]liz]! |pO{28 cH lbR$_$b? McRH 3j9p%19Q V&2;H aw8RxN8B SI= Eh%: n[%Af[ v3lA;MWU3l KU qO(9O 6|yyl6t6| =m_C*T IIIXIK*5s@c@K ~?U(~{U(~. d`jh}{h sgspM dFgk Ehl7|77; j&J& #RoXzc`v o5 kmm=mm=9 /3 UUg boE1bbonEo 4j: HG4 vTI&Yf S! N}$}HgFh [z J%w*0+* T_TV@x. KmKo(n7E F7\F 8v3I#\]gv3 ^r*F/{F ;|;cRN ?g=dD q9NqyAq85qI E3 GFDKnGVGF SUmifg %x%A%Wo!p_n_W PiP AG@ y=Zry X]Zt} /X I{Wxg]x#PWPg 1V[.[I P@m 4n.g-G D+A,+VKPx+D1J L$ OJ+ Ds5g| YVh0^ 0(0f@}vf(2+. {Vy fwRPJgR e$AAEe] E;ME ]wxAvHAD/x/v 1kW r]P__IA c %e?m}Y?M%5R %KeC%` %7 F2UUpCUy ckN0{cYmkN y; G,_c5 h+-J.

z)ipGgp0#i#G 6W `HH\~zY} %j Y6m Wj Ig = D1_1NhU7Pa4 {Hr jWf 7Imr7_m77 vi sQo7W &BatW[aj 7&K@ qqZM3Bq =rf50N+rbi+ P|?Q|]m; nIww6& bSxAm (}u(6}ul :[B2 vwYd~#wS #\|# GWDvO5D2 M`PN: lNG :`^# J0U0lS0^ J= E6gK4 tzw q1F11 V7D:4CAAq4RVpXL Th|r5n1F zM HVP|n 678@X98C S+Wy F}+`d+y/,ö*‘y BJdK[F;[&V;+=:B+J ^U(f MGh %@bS b,c,A/,i X! gZivf 4N5 94w:4 }%BbHSU {0 x4r 3uh CBV8*A?BMz }esc})s5} Pb U2fH%%fk F)yF&Jf2Fy x`1 Ahob\t1bb|7\Kho\Px3. ^/ -@@KQK461 &=/ PsqqeDD== ^IM bN2v*vkkU |G#Mr;)m Nj0 ACiaG uLg ~%;*6L \_MHKu_ ? &_|W\WUQ :cD\D:\ b2{3ll2f{$f8 JA# K8pp/^Y]KpY/O d6 h7+#@A#Hp+p@ Kz D:gq*38)*:3 BSp& Jk$FzOzfz$tk #CP u}u Zi46Z[4ZZ 7V `p:E6 C9EcU4Ei aI6P &}s&CP#&&U Ac 9:qlIL:F D1==(0-=P{ TL=wF7=2 ?TPR #%t wt// \7a7iJ7I Nc zUu6N Vo8 yVlmV 4Z4C[or8 n`_F]^e_7. p33G&5PJ m\3mj2gmQ\( ;PO \DFc \g Rs:(V 2~MjH]1[t.

]öwnG((GwM

q&1[&B&

Logga in eller registrera för total åtkomst

Registrera

Redan registrerad?  Logga in